AstraZeneca’s Imfinzi fails to meet main goals in head and neck cancer study
The study, known as 'EAGLE', did not improve overall survival compared with standard chemotherapy in patients with the…
Author
Lupin’s Pithampur Unit-3 receives EIR from US FDA
The facility manufactures dermatological products, dry product inhalers and metered dose inhalers
Alembic Pharmaceuticals gets US FDA nod for ophthalmic solution
The approved product is therapeutically equivalent to the reference listed drug product Patanol ophthalmic solution, 0.1 per cent,…
DRL launches chlorthalidone tablets, USP in the US market
The tablets are available in 25 mg tablets in the bottle-count sizes of 100 and 1000, and 50 mg tablets
Canadian delegation to showcase investment opportunities to India
The delegation will visit Bengaluru and Mumbai from November 26 to 30
Lupin launches chatbot ANYA
ANYA is the first bot of its kind to be launched in India for disease awareness
ABLE’s BioEconomy Conclave to be held in Bengaluru
The two-day conclave from January 31 to Febrauary 1, will have nine sessions dedicated to different segments of bioeconomy
Strides board approves $15 m investment in Stelis Biopharma
The first close of the current fund raise is $35 million, of which Strides will commit $15 million and $20 million is from other…
Roche-AbbVie cancer drug gets accelerated FDA approval
The drug, developed in partnership with AbbVie, was approved for patients with acute myeloid leukemia
US FDA approves new blood cancer treatment from Pfizer
The company plans to launch the drug, Daurismo, in the US by early December with a monthly list price of $16,925